Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab

Early tumor shrinkage (ETS) is associated with long-term outcome in patients with chemorefractory metastatic colorectal cancer (mCRC) receiving cetuximab. This association was investigated in the first-line setting in the randomized CRYSTAL and OPUS mCRC trials, after controlling for KRAS tumor muta...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of clinical oncology Ročník 31; číslo 30; s. 3764
Hlavní autori:	Piessevaux, Hubert, Buyse, Marc, Schlichting, Michael, Van Cutsem, Eric, Bokemeyer, Carsten, Heeger, Steffen, Tejpar, Sabine
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 20.10.2013
Predmet:	Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cetuximab Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Disease-Free Survival Female Humans Kaplan-Meier Estimate Male Middle Aged Neoplasm Staging Predictive Value of Tests Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics ROC Curve Sensitivity and Specificity Time Factors Treatment Outcome
ISSN:	1527-7755, 1527-7755
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!